Post
Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial – ScienceAlert
- Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial ScienceAlert
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s cnbc.com
- Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs Scientific American
- ‘Godzilla’ of weight-loss drugs could provide other important health benefits The Guardian
- Lilly raises diabetes weight-loss bar with amylin-Zepbound combo Fierce Biotech